Valink Therapeutics
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
Y Combinator
yc-company-directory #4603Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
sourceValink Therapeutics is classified as Developer tools from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.
Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.
Companies similar to Valink Therapeutics
A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.
GEn1E Lifesciences
match 86GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to
shared product terms: target, develop, novel, next; shared product theme: health and clinical care; shared affiliation: Y Combinator
Notable Labs
match 54Notable Labs is building a personalized drug discovery platform to identify treatment options for relapsed and refractory cancer patients — starting with blood cancer — to address the long tail of cancer treatment. We look at a person’s actual cancer cells, test combinations of FDA approved drugs, and see which combinations kill the cancer cells and leave the healthy cells alive. We focus on combinations because cancer is often difficult to target with just one drug and starting with a single dr
shared product terms: drug, discovery, identify, focu; shared product theme: health and clinical care; shared affiliation: Y Combinator
Reflector Bio
match 48Reflector Bio is transforming drug discovery by bringing functional biology to the forefront. Our AI platform predicts how compounds behave in human cells, improving translational relevance and predictive power across diverse assays. By combining large-scale phenotypic data with advanced machine learning, we uncover mechanisms of action, identify novel biology, and guide experimental design with precision.
shared product terms: drug, discovery, mechanism, action
Sequence Bio
match 4390% of drug candidates fail, delaying help for those in need. We’re on a mission to change that. Better drug target discovery powered by the Newfoundland founder effect.
shared extracted concept terms: target; shared product terms: drug, candidate, target, discovery; shared affiliation: Y Combinator
Asher Bio
match 43Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmu
shared extracted concept terms: target; shared product terms: develop, target, address, multiple; shared affiliation: Y Combinator
Eris Biotech
match 38We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma.
shared product terms: develop, therapeutic, drug, solid; shared product theme: health and clinical care; shared affiliation: Y Combinator